Argent BioPharma Limited
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I c… Read more
Argent BioPharma Limited (RGTLF) - Total Liabilities
Latest total liabilities as of June 2025: $11.10 Million USD
Based on the latest financial reports, Argent BioPharma Limited (RGTLF) has total liabilities worth $11.10 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Argent BioPharma Limited - Total Liabilities Trend (2020–2025)
This chart illustrates how Argent BioPharma Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Argent BioPharma Limited Competitors by Total Liabilities
The table below lists competitors of Argent BioPharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xin Hwa Holdings Bhd
KLSE:5267
|
Malaysia | RM209.05 Million |
|
Bluechiip Ltd
AU:BCT
|
Australia | AU$3.94 Million |
|
Cover Technologies Inc
PINK:MGPRF
|
USA | $1.77 Million |
|
I2 Enterprise Public Company Limited
BK:I2
|
Thailand | ฿1.15 Billion |
|
CDRL SA
WAR:CDL
|
Poland | zł99.16 Million |
|
AMD Industries Limited
NSE:AMDIND
|
India | ₹1.06 Billion |
|
H2 Ventures 1 Inc.
V:HO-P
|
Canada | CA$30.85K |
|
Jacob Finance And Investments Ltd
TA:JCFN
|
Israel | ILA2.24 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Argent BioPharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Argent BioPharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Argent BioPharma Limited (2020–2025)
The table below shows the annual total liabilities of Argent BioPharma Limited from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $11.10 Million | -33.20% |
| 2024-06-30 | $16.61 Million | -7.79% |
| 2023-06-30 | $18.02 Million | +34.66% |
| 2022-06-30 | $13.38 Million | +28.51% |
| 2021-06-30 | $10.41 Million | +115.31% |
| 2020-06-30 | $4.83 Million | -- |